Establishment of a tumor-informed cfDNA Methylation Signature for head and neck Squamous Cell Carcinoma (HNSCC)
Laryngo-Rhino-Otologie · 01.05.2024 · 103 (S 02 S 02) · S223
DOI: 10.1055/s-0044-1784729 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2024. Verfasst von Lukas Boosfeld und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
As translational methods improve, liquid biopsies are becoming increasingly relevant in early detection, therapy monitoring, and tumor surveillance. CfDNA has been proposed as a potential analyte, however clinical translation has been limited by cost and technological constraints. Here, we evaluate a novel technology of reduced representation bisulfite sequencing for investigation of cfDNA methylation in HNSCC.
Methods
A pan-cancer cfDNA methylation panel established by whole genome bisulfite sequencing was used to score cfDNA methylation in HNSCC patients. Tumor relevance of identified differential methylated positions (DMPs) was assessed by projecting to tumor data from the TCGA. Samples included n=8 HNSCC (2x oral cavity, 2x laryngeal, 2x p16+and 2x p16- oropharyngeal).
Results
The Panel identified 1454 common hypermethylation sites between patient cfDNA and TCGA tissue data (15 entities). When these were applied to n=8 HNSCC serum samples not included in the discovery cohort, distinctive cfDNA methylation patterns were nonetheless observed compared to healthy donor samples, such as cg151460939 and cg196978984 on chromosome 3 (p=0.001 and p=0.02, resp.). Further, specific DMPs not only differentiated between HNSCC and other tumor entities, but also between p16+and p16- HNSCC, for example cg05756685 and cg03358154 (p=0.017 and p=0.019, resp.). Additionally, the certain DMPs such as cg02705958 and cg00472710, were prognostic for survival when tested in the TCGA dataset (low vs. high HR: 0.20, p=0.027 and HR: 1.97, p=0.013, resp.).
Conclusion
This study contributes to a better understanding of cfDNA methylation in HNSCC and identifies DMPs that could be tested for their biomarker potential in future larger and prospective trials. Publication History Article published online: 19 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Boosfeld, L., Bruderek, K., Lang, S., Brandau, S., Lueong, S. S., & Kürten, C. (2024). Establishment of a tumor-informed cfDNA Methylation Signature for head and neck Squamous Cell Carcinoma (HNSCC). Laryngo-Rhino-Otologie, 103(S 02 S 02), S223. https://doi.org/10.1055/s-0044-1784729
Vancouver
Boosfeld L, Bruderek K, Lang S, Brandau S, Lueong SS, Kürten C. Establishment of a tumor-informed cfDNA Methylation Signature for head and neck Squamous Cell Carcinoma (HNSCC). Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S223. doi:10.1055/s-0044-1784729
BibTeX
@article{Boosfeld2024,
author = {Boosfeld, Lukas and Bruderek, Kirsten and Lang, Stephan and Brandau, Sven and Lueong, Smiths Sengkwawoh and Kürten, Cornelius},
title = {Establishment of a tumor-informed cfDNA Methylation Signature for head and neck Squamous Cell Carcinoma (HNSCC)},
journal = {Laryngo-Rhino-Otologie},
year = {2024},
volume = {103},
number = {S 02 S 02},
pages = {S223},
doi = {10.1055/s-0044-1784729}
}
EUVIMED